Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III

Executive Summary

Primary endpoint miss for Phase III selonsertib in cirrhotic NASH patients follows disappointing data at both 2018 major liver conferences. STELLAR-3 in NASH patients with bridging fibrosis looms large for Gilead’s hopes.

Advertisement

Related Content

In NASH, Gilead Swung For The Fences And Struck Out Again
Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Genfit May Be Gaining An Edge In NASH Race
Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit
Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel